The cell therapy researcher that can change “bad cells” to “good cells”

More and more people are suffering from metabolic disorders, ranging from obesity to diabetes. Although many drugs have been developed for these disorders, some of them have been associated with dangerous side-effects. Many scientists are working tirelessly to find better and safer medicine.

The search for Sibutramine alternatives

Around 2010, cell therapy researchers discovered that Sibutramine, an appetite suppressant, was associated with increased cardiovascular events and strokes, and the medicine was withdrawn from the market. Subsequently, many scientists looking for alternatives set their sights on the fat cells themselves. There are two types of fat cells in the human body: white fat cells (the “bad” cells), which store energy, and brown fat cells (the “good” cells), which turn fat into energy. Dr. Li Jin, a young researcher from Fudan University, has found a peptide that can act on white fat cells to stimulate the expression of brown-fat-like activities in mice. This finding could lead to further clinical research for promising new medication to treat obesity.

Dr. Li is also working on turning non-insulin-secreting α cells into insulin-secreting β-like cells. This could bring renewed hope for patients with Type 1 diabetes.

Experience of a young researcher in the cell therapy field

Although Jin Li is still a young researcher, he has gained broad experience across Asia, Europe, and the US. After receiving a Master’s Degree from Li Ka Shing Faculty of Medicine, The University of Hong Kong, Li continued his research in Europe and received a Ph.D. from the Research Center for Molecular Medicine of the Austrian Academy of Sciences. He was also a research fellow at Harvard Medical School before eventually returning to Fudan University in China. Li found significant differences between the various research environments: “The research center in Austria was not big, however, there was a very high level of collaboration among all researchers. There were 150 researchers in total. Everyone knew the other 149.” Li was very impressed by how efficient the center was. “Things in Harvard Medical School happen very fast. It was challenging for a researcher, but also good learning experience.” And recalling his experience in China, Li was struck by how much support junior researchers got from the authorities. “Young researchers don’t receive that level of support in the US”.

And how long does Li think it will take for his research to benefit patients with obesity and diabetes? Search Jin Li’s predictions regarding new treatments in the Pro app by typing “obesity” and “Type 1 diabetes” respectively. Not an app user yet? Visit the Supertrends Pro – page to learn about your benefits and request a trial – for free!

© 2020 Supertrends

Cell Therapy, Diabetes, α cells

Jiqing Hansen

Having worked passionately for 15+ years in Medicine, I felt that I yearned to do something a little bit different, something that satisfies my curiosity and creativity, maybe something that helps to inform me and others what our world will look like in the future. That's when I took on the challenge of being the editor & expert relationship manager at Supertrends. I love the fact that I can still be in touch with my academic background when I am trying to understand and reach out to the experts in the most exciting fields. I also love the diverse and enthusiastic team at Supertrends. The best of all, I get to have a peek into the future, and I am at the position of helping many others to get the opportunity to look into the future.

Join us


Sign up for our Newsletter


Supertrends AG, Erlenstrasse 16, 6300 Zug